Nonspecific enhancers of resistance in man.
Nonspecific enhancers of resistance may include (1) viral interference, (2) interferon, (3) interferon inducers, (4) bacterial interference, (5) bacterial products such as Coley's "toxins," endotoxins, or staphylococcal, BCG, and Corynebacterium parvum vaccines, (6) transfer factor, and (7) well-defined chemicals such as dinitrochlorbenzene, levamisole, and vitamin C. These are discussed only as they have been applied to man to learn whether or not they have enhanced his ability to resist infections and growth of tumors. Preliminary studies suggest that a variety of relatively safe and effective nonspecific enhancers may soon be available for clinical use.
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D001205:Ascorbic Acid / Q000627:therapeutic use; D001500:BCG Vaccine / Q000627:therapeutic use; D001419:Bacteria / Q000378:metabolism; D004137:Dinitrochlorobenzene / Q000627:therapeutic use; D004731:Endotoxins / Q000502:physiology; D006801:Humans; D007109:Immunity / Q000187:drug effects*; D007111:Immunity, Cellular / Q000187:drug effects; D007369:Interferon Inducers / Q000494:pharmacology; D007372:Interferons / Q000627:therapeutic use; D007978:Levamisole / Q000627:therapeutic use; D008545:Melanoma / Q000188:drug therapy; D051379:Mice; D011425:Propionibacterium acnes / Q000276:immunology; D051381:Rats; D012141:Respiratory Tract Infections / Q000628:therapy; D012878:Skin Neoplasms / Q000188:drug therapy; D013209:Staphylococcal Vaccines / Q000627:therapeutic use; D014165:Transfer Factor / Q000627:therapeutic use; D014762:Viral Interference
D000276:Adjuvants, Immunologic; D001500:BCG Vaccine; D004137:Dinitrochlorobenzene; D004731:Endotoxins; D007369:Interferon Inducers; D013209:Staphylococcal Vaccines; D014165:Transfer Factor; D007978:Levamisole; D007372:Interferons; D001205:Ascorbic Acid